CHRONO-LOG CORP.

CHRONO-LOG CORP. designs, develops, and manufactures innovative platelet function testing systems for clinical and research laboratories. The company specializes in platelet aggregation and secretion methodologies used to diagnose platelet function defects, monitor anti-platelet drug therapy, and identify bleeding or thrombotic risk in patients. CHRONO-LOG offers three primary testing platforms: Whole Blood/Impedance Aggregation for rapid platelet function screening in physiologic whole blood environments with reduced sample preparation; Optical/Light Transmission Aggregation (LTA) using dual-beam detection for improved sensitivity with micro-volume samples (250 µL); and ATP Release analysis for quantitative measurement of dense granule secretion and simultaneous aggregation-secretion studies. The company also provides Ristocetin CoFactor Assay systems for Von Willebrand Disease diagnosis, with capabilities to detect Type 3 disease at 3% activity levels. CHRONO-LOG systems are used to diagnose specific platelet disorders including Von Willebrand Disease, Glanzmann's Thrombasthenia, Storage Pool Disease, and secretion defects. The platform supports PRP, washed, and gel-filtered platelet testing. CHRONO-LOG's aggregation systems and reagents are FDA-cleared and CE-marked. The company serves hematology, hemostasis, and thrombosis laboratories globally, supporting patient risk stratification, anti-platelet drug selection and monitoring, and research into novel hemostatic therapies. CHRONO-LOG emphasizes reduced blood draw volumes, faster turnaround times, and lower labor intensity compared to alternative platelet function testing methods.